- New research shows that people are much more likely to adhere to newer semaglutide medications for long-term weight loss than older anti-obesity drugs.
- Semaglutides such as Wegovy, Ozempic, and Rybelsus were developed to treat type 2 diabetes but are also being prescribed for obesity.
- Accessibility to these newer drugs is an issue with frequent shortages, high costs, and inconsistent insurance coverage.
- While new drugs can make a significant difference when it comes to weight loss, experts say lifestyle changes are necessary for long-lasting results.
In recent years, semaglutide medications sold under the brand names Wegovy, Ozempic, and Rybelsus have been a game-changer when it comes to treating not just type 2 diabetes but also obesity.
Now, new
The findings were published last week in the medical journal Obesity and experts say they offer some intriguing insights into the long-term use of anti-obesity medications.
The study’s lead author told Medical News Today that positive results from the newer drug could help explain the long-term adherence.
Glucagon-like peptide-1 receptor agonists, or
These drugs can help people curb unhealthy eating habits by stimulating hormones, which suppresses the appetite. They also help the stomach empty more slowly, leading to a more long-lasting feeling of being full.
Hamlet Gasoyan, PhD, the lead author of the study and a researcher with Cleveland Clinic’s Center for Value-Based Care Research, set out to explore whether patients were willing to stick with these prescriptions to…
Read the full article here